Share Purchase Plan (SPP) Offer Booklet
Released
Released
Announcement PDF
Antisense Therapeutics Limited
ACN 095 060 745
(ASX:ANP)
Share Purchase Plan Booklet
Eligible Shareholders have the opportunity to participate in the Offer by applying for up
to A$30,000 worth of Shares without incurring brokerage, commissions, stamp duty or
other transaction costs. Details of the Offer and how to participate are set out in these
Terms and Conditions. Shares issued under the Offer will rank equally in all respects
with all other Shares on issue as at the date of issue and will carry the same voting
rights, dividend rights and other entitlements as those Shares.
This Share Purchase Plan Booklet is dated 28 July 2023.
This Share Purchase Plan Booklet may not be released to US wire services or distributed in the United States.
Important Information
This document is intended for use only in connection with the Offer to Shareholders in Australia and New
Zealand. No action has been taken to permit an offering of Shares in any jurisdiction outside of Australia
and New Zealand. The distribution of this document may be restricted by law and persons (including
Custodians, trustees and nominees) who come into possession of this document should observe any
such restrictions.
New Zealand
The Shares under the Offer are not being offered or sold to the public within New Zealand other than to
existing Shareholders of the Company with registered addresses in New Zealand to whom the Offer is
being made in reliance on the Financial Markets Conduct (Incidental Offers) Exemption Notice 2021.
This document has been prepared in compliance with Australian law and has not been registered, filed
with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013.
This document is not a product disclosure statement under New Zealand law and is not required to, and
may not, contain all the information that a product disclosure statement under New Zealand law is
required to contain.
United States
This document does not constitute an offer to sell, or the solicitation of an offer to buy, securities in the
United States and may not, directly or indirectly, be distributed in the United States. The Shares under the
Offer have not been, and will not be, registered under the U.S. Securities Act or the securities laws of any
state or other jurisdiction of the United States and, accordingly, the Shares may not be directly or
indirectly, offered, sold, resold or transferred in the United States, except pursuant to an exemption from
the registration requirements of the U.S. Securities Act and applicable state securities laws. The Shares
will only be offered and sold outside the United States in compliance with Regulation S under the U.S.
Securities Act.
Not financial product advice
ANP is not licensed to provide financial product advice in relation to the Shares issued under the Plan or
any other financial products and nothing in this document constitutes investment or financial product
advice or is intended to influence your decision whether or not to participate in the Plan. The Offer of new
Shares under the Plan is not a recommendation by ANP to acquire Shares. No cooling off regime applies
in respect of the acquisition of Shares under the Plan (whether the regime is provided for by law or
otherwise). Eligible Shareholders must rely on their own knowledge of ANP, previous disclosures made
by ANP to the ASX and, if necessary should obtain their own advice on whether or not to participate in
the Plan (taking into account their own financial situation, needs and objectives).
Letter from the Chair
28 July 2023
Dear Shareholder
Antisense Therapeutics Limited – Share Purchase Plan
I am pleased to invite you to participate in the offer of fully paid ordinary shares (Shares) in Antisense
Therapeutics Limited ACN 095 060 745 (ANP or Company) under the share purchase plan established
by ANP (Plan or Offer).
The Company is providing an opportunity for existing shareholders to strengthen their position on the
same terms as our recent institutional placement. The Offer is not underwritten.
The Directors of the Company have indicated their intention to participate in the Offer, subject to eligibility.
Overview of the Offer
On 18 July 2023, the Company announced to ASX a placement of new Shares to institutional and
sophisticated investors (Placement) to raise approximately A$8.35 million at an issue price of A$0.05 per
Share (Placement Price).
Further details of the Placement are set out in the ASX announcements dated 18 July 2023 and released
to ASX on that date. Morgans Corporate Limited ACN 010 539 607 acted as lead manager to the
Placement.
The Board recognises that a number of the Company's loyal Shareholders did not have an opportunity to
participate in the Placement. The Board is therefore pleased to offer Eligible Shareholders (as defined in
the Terms and Conditions below) an opportunity (subject to certain conditions), to acquire a minimum of
A$2,500 and up to, in aggregate, A$30,000 of Shares in ANP (free from any brokerage or transaction
costs) at an issue price equal to the Placement Price, being A$0.05 per Share (Issue Price).
ANP is targeting to raise up to approximately A$1.5 million under the Offer. In accordance with section 8
of the Plan, the Company reserves the right in its sole and absolute discretion to increase or decrease the
final amount raised under the Offer including based on overall applications received. Similarly, the
Company reserves the right to scale back applications in its sole and absolute discretion.
If applications are scaled back, excess funds will be returned to applicants without interest.
Participation in the Offer is optional and is open to Eligible Shareholders who, as at the Record Date
(7:00pm (Sydney time) on 19 July 2023), were registered as holders of fully paid ordinary shares in ANP
and whose address on the share register is in Australia or New Zealand.
If an Eligible Shareholder holds Shares as a Custodian the Offer is also being made to the Custodian
and, subject to certain conditions, the Custodian has the discretion to extend the Offer to the relevant
beneficiaries.
The Offer is being undertaken in conjunction with, and supplemental to, the Placement, to principally
continue the ongoing international Phase IIb Clinical Trial program for ATL1102 in Duchenne muscular
dystrophy, as well as for ongoing working capital.
More detail on the proposed use of funds is contained in the information released to ASX in relation to the
Placement on 18 July 2023.
Antisense Therapeutics Limited | Share Purchase Plan
Page 3
Timing*
The Offer will be undertaken in accordance with the indicative timetable below.
Event
Date*
Record Date (the business day prior to ANP's
announcement of the Plan)
Wednesday, 19 July 2023
Opening Date
Friday, 28 July 2023
Closing Date
Wednesday, 16 August 2023
Announcement of the results of the Offer
Monday, 21 August 2023
Issue Date (i.e. the date of issue of Shares under the
Offer)
Tuesday, 22 August 2023
Expected date for quotation of Shares issued under
the Offer on ASX
Wednesday, 23 August 2023
Despatch of holding statements in respect of Shares
issued under the Offer
Wednesday, 23 August 2023
(Australian Eastern Standard Time)
* The timetable is indicative only and subject to change. ANP retains the right, subject to the ASX Listing Rules and the
Corporations Act, to alter any or all of these key dates at its discretion (generally or in particular cases), without prior notice,
including extending the Closing Date or to withdraw the Plan without prior notice. Eligible Shareholders are encouraged to submit
their applications as soon as possible.
If you decide to take this opportunity to participate in the Offer, you need to pay by BPAY® online or by
telephone. You do not need to fill in or return any forms. Payments by cash, cheque, bank draft or money
order will not be accepted. To pay via BPAY® you will need to:
(a)
be an account holder with an Australian financial institution;
(b)
use your unique customer reference number set out in the instructions provided in your
personalised application form, which identifies your shareholding. You MUST use the specific
biller code and unique reference number on your personalised application form, or your
application may not be able to be reconciled and your application monies may be returned to you;
and
(c)
ensure that your payment is received by the Company's share registry, Boardroom Pty Limited,
before 5.00pm (Sydney time) on 16 August 2023. You should be aware that your own financial
institution may implement earlier cut-off times with regard to electronic payment, and you should
therefore take this into consideration when making payment. It is your responsibility to ensure
that funds submitted through BPAY® are received by the Closing Date, unless the Offer is
extended.
Eligible Shareholders unable to pay via BPAY®, excluding those whose registered address is in New
Zealand, will need to contact Boardroom Pty Limited from 9.00am to 5.00 pm (Sydney time), Monday to
Friday (excluding public holidays) on 1300 737 760 (within Australia) or 02 9290 9600 (outside Australia)
to obtain alternative payment instructions.
Eligible Shareholders whose registered address is in New Zealand will be sent a separate letter that will
have the bank account details and instructions on how to make payment by EFT. Eligible Shareholders
who pay by EFT must return a copy of their duly completion personalised application form in accordance
with the payment instructions provided.
Antisense Therapeutics Limited | Share Purchase Plan
Page 4
Further information
Participation in the Plan is completely optional. However, an Eligible Shareholder's entitlement to
participate in the Plan is non-renounceable. This means that an Eligible Shareholder's right to participate
in the Plan cannot be transferred to anyone else.
In deciding whether to participate in the Offer, you should seek your own independent financial, legal and
taxation advice in respect of the Offer. No cooling off regime applies to the acquisition of Shares under
the Offer.
On behalf of the Board, I thank you for your continued support of ANP and I invite you to consider
participating in the Offer.
Yours faithfully
Dr Charmaine Gittleson
Executive Chair
Antisense Therapeutics Limited
Antisense Therapeutics Limited | Share Purchase Plan
Page 5
TERMS AND CONDITIONS OF THE PLAN
Establishment
The Plan is established under ASIC Corporations (Share and Interest Purchase Plans) Instrument
2019/547 (ASIC Instrument) and in accordance with ASIC Regulatory Guide 125 and the ASX
Listing Rules. The ASIC Instrument grants relief from the requirements under the Corporations
Act to issue a disclosure document for the offer of Shares under the Plan, subject to the
satisfaction of certain conditions.
This document does not constitute a prospectus or product disclosure statement and has
not been, and will not be, lodged with ASIC.
2.
Participation
The Board may make offers under the Plan to all persons who, as at the Record Date, are Eligible
Shareholders.
You are an Eligible Shareholder if you were a registered holder of Shares at the Record Date
(7.00pm (Sydney time) on 19 July 2023) and had a registered address in Australia or New
Zealand (as recorded on ANP's share register) unless:
(a)
you hold shares on behalf of another person who resides outside Australia or New
Zealand in which case you will not be eligible to participate in respect of the Shares of that
person; or
(b)
you are in the United States or acting for the account or benefit of a person in the United
States.
ANP has determined that it is not practical for a holder of Shares with a registered address (as
recorded on ANP's share register) in any jurisdiction other than Australia or New Zealand, to
participate in the Offer. No Offer is made to persons who are not Eligible Shareholders.
In order to comply with relevant securities laws, the Shares to be issued under this Plan may not
be offered to Shareholders located in the United States or to Shareholders who are, or who are
acting for the account or benefit of, persons in the United States.
Because of these legal restrictions, you must not send copies of this document or any other
material relating to the Plan to any person resident in the United States or elsewhere outside
Australia and New Zealand.
Participation in the Offer by Eligible Shareholders is optional and is subject to these Terms and
Conditions.
3.
Offer
3.1
Nature of offer
The Offer is non-renounceable and Shares may be issued under the Plan only to the Eligible
Shareholder.
The Offer will be made on these Terms and Conditions to each Eligible Shareholder. All Eligible
Shareholders will receive the same offer, irrespective of the number of Shares which they hold on
the Record Date.
Antisense Therapeutics Limited | Share Purchase Plan
Page 6
3.2
Plan participation rules
The following rules apply to participation by Eligible Shareholders:
Single holders
Unless a holder is a Custodian, each Eligible Shareholder is entitled to apply under the Offer for
up to a maximum amount of A$30,000 worth of Shares (irrespective of whether the holder
receives multiple Offer documents, for example, due to multiple registered sole or joint holdings),
subject to the holder certifying that the total of the application price for the following does not
exceed A$30,000:
(a)
the Shares the subject of the application;
(b)
any other Shares applied for by the holder under the Plan or any similar arrangement in
the 12 months before the application;
(c)
any other Shares which the holder has instructed a Custodian to acquire on their behalf
under the Plan; and
(d)
any other Shares issued to a Custodian under an arrangement similar to the Plan in the
12 months before the application as a result of an instruction given by the holder to the
Custodian or another Custodian which resulted in the holder holding beneficial interests in
the Shares.
By completing and submitting an application for Shares under the Offer, a holder certifies the
above.
Joint holders
Unless a holder is a Custodian, if an Eligible Shareholder is recorded with one or more other
persons as a joint holder of Shares, that joint holding is considered to be a single registered
holding for the purpose of the Plan and certifications or representations given by a joint holder are
taken to have been given by all joint holders. Joint holders are only entitled to participate in the
Offer in respect of that single holding. If the same joint holders receive more than one Offer
document due to multiple identical holdings, the joint holders may only apply for one maximum
amount of A$30,000 worth of Shares.
Custodians
If an Eligible Shareholder holds Shares as a Custodian, the Offer is made to the Custodian and,
subject to certain conditions, the Custodian has the discretion to extend the Offer to the
Beneficiaries. The Custodian may apply for up to a maximum amount of A$30,000 worth of
Shares in respect of each Beneficiary. However, ANP will not allocate Shares under the Offer to
the Custodian unless the Custodian certifies the matters set out in a Custodian Certificate.
Custodians wishing to participate in the Offer on behalf of one or more Beneficiaries should
contact Boardroom Pty Limited from 9.00am to 5.00 pm (Sydney time), Monday to Friday
(excluding public holidays) on 1300 737 760 (within Australia) or 02 9290 9600 (outside Australia)
to obtain further information on how to apply and how to obtain a Custodian Certificate. If a
Custodian holds Shares jointly on behalf of two or more Beneficiaries, the A$30,000 limit applies
jointly in relation to those Beneficiaries as if the Custodian held the Shares on behalf of a single
person.
A Custodian must not participate in the Plan if their participation in the Plan would breach the
ASIC Instrument.
3.3
Other terms
The Offer opens at 9.00am (Sydney time) on 28 July 2023. The Offer closes at 5.00pm (Sydney,
time) on 16 August 2023, unless the Offer is extended. Under the Offer you may apply for Shares
up to a maximum value of A$30,000 and you must apply for a minimum value of A$2,500 worth of
Shares. The Offer will be made subject to any other terms and conditions that the Board
considers reasonable and appropriate.
Antisense Therapeutics Limited | Share Purchase Plan
Page 7
4.
Issue Price
Shares will be issued under the Offer at the Issue Price, being A$0.05 per Share, which
represents a 18% discount to the last closing price of A$0.061 per Share on 19 July 2023, which
was the last day of trading of Shares on ASX prior to ANP's announcement of the Offer. The
Issue Price is the same as the recently announced Placement.
Important Note: Shareholders should note that there is a risk that the market price of
Shares may change between the date of the Offer and the date on which Shares are issued
under the Plan. This means it is possible that, between the time you make your application
and the date on which Shares are issued under the Plan, you may be able to buy Shares at
a lower price than the Issue Price. No cooling-off regime applies in relation to the
application for or acquisition of Shares under the Plan.
5.
Risks associated with the Offer
Shareholders should note that there is a risk that the market price of Shares may change between
the time you make your application and the date on which Shares are issued under the Plan.
No cooling off regime applies in relation to the application for or acquisition of Shares under the
Plan.
There are also a number of other risks associated with an investment in Shares under the Offer.
Further details about these risks and ANP generally are included in the 'Key Risks' section of
ANP's 2022 annual report released to the ASX on 19 October 2022, which you are encouraged to
read.
ANP is a disclosing entity for the purposes of the Corporations Act and, as a result, is subject to
regular reporting and disclosure obligations under the Corporations Act and the ASX Listing
Rules. ANP recommends that before deciding whether or not to apply for Shares under this Offer,
you refer to the current market price of the Shares which can be obtained from the financial pages
of major metropolitan and national newspapers, your stockbroker or the ASX (www.asx.com.au)
(ASX code: ANP). ANP also recommends that you monitor ANP announcements, which can be
found on ANP's website at https://www.antisense.com.au/asx-announcements/ or on ASX's
website.
6.
Costs of participation
The only cost to you in relation to your participation in the Offer will be the application money paid
for Shares that you wish to apply (up to A$30,000). No brokerage, commissions, stamp duty or
other transaction costs will be payable by Eligible Shareholders in respect of the application for,
and issue of, Shares under the Plan.
7.
Acceptance of Offers
7.1
Payment method
All amounts in this Offer are expressed in Australian dollars.
Eligible Shareholders who wish to apply for Shares under the Offer must make a payment by
BPAY® in accordance with the instructions provided in or accompanying this document so that
cleared funds are received by Boardroom Pty Limited prior to 5.00pm (Sydney time) on
16 August 2023.
To pay via BPAY®, Eligible Shareholders will need to:
(a)
be an account holder with an Australian financial institution;
(b)
use their unique customer reference number set out in the instructions provided in your
personalised application form, which identifies your shareholding. You MUST use the
Antisense Therapeutics Limited | Share Purchase Plan
Page 8
specific biller code and unique reference number on your personalised application form, or
your application may not be able to be reconciled and your application monies may be
returned to you; and
(c)
ensure that payment is received by Boardroom Pty Limited prior to 5.00pm (Sydney time)
on 16 August 2023.
You can only make payment by BPAY® if you are the holder of an account with an Australian
financial institution that supports BPAY® transactions. There is no need to return the personalised
application form, but you will be taken to have made the statements and certifications that are set
out in these Terms and Conditions and in your personalised application form. You should be
aware that your own financial institution may implement earlier cut-off times with regard to
electronic payment and you should therefore take this into consideration when making payment.
It is your responsibility to ensure that funds submitted through BPAY® are received by the Closing
Date, unless the Offer is extended.
Eligible Shareholders who receive more than one Offer under the Plan (for example, because
they hold Shares in more than one capacity or in different registered holdings) may not apply and
pay for Shares with an aggregate value of more than A$30,000.
Eligible Shareholders unable to pay by BPAY®, excluding those whose registered address is in
New Zealand, will need to contact Boardroom Pty Limited from 9.00am to 5.00 pm (Sydney time),
Monday to Friday (excluding public holidays) on 1300 737 760 (within Australia) or 02 9290 9600
(outside Australia) to obtain alternative payment instructions.
Eligible Shareholders whose registered address is in New Zealand will be sent a separate letter
that will have the bank account details and instructions on how to make payment by EFT. Eligible
Shareholders who pay by EFT must return a copy of their duly completion personalised
application form in accordance with the payment instructions provided.
7.2
Further information
Applications must be received by 5.00pm (Sydney time) on the Closing Date.
Eligible Shareholders may apply for Shares under the Offer in parcels valued at A$2,500,
A$5,000, A$10,000, A$20,000 or A$30,000.
If you apply for Shares, you will apply for a certain value, rather than a certain number, of Shares.
If your application is accepted and in the absence of a scale back in accordance with section 8
below, ANP will divide the application money of an Eligible Shareholder by the Issue Price in
order to determine the number of Shares for which they have applied (rounded down to nearest
whole number of Shares).
If ANP receives an amount that does not equal one of the amounts specified above, the Company
may either:
(a)
reject the application and refund in full the application money (without interest) to the
Eligible Shareholder; or
(b)
apply the dollar amount of the payment to the highest designated parcel that is less than
the amount of the payment and refund the excess application money (without interest) to
the Eligible Shareholder.
If you have more than one holding of Shares and consequently receive more than one
personalise application form, when applying for Shares in respect of one of those shareholdings
you must only use the customer reference number specific to that shareholding as set out in the
relevant personalised application form. Do not use the same customer reference number for
more than one of your shareholdings. This can result in your application monies being applied to
your application in respect of only one of your shareholdings (with the result that any application in
respect of your remaining shareholdings will not be recognised as valid).
If one or more applications are received under the Plan from an Eligible Shareholder in relation to
Shares with a value greater than A$30,000 in any 12 month period, the Shareholder will be issued
with the maximum number of Shares permitted by the Plan and the terms of the Offer. Any
Antisense Therapeutics Limited | Share Purchase Plan
Page 9
excess subscription monies will be refunded to the Eligible Shareholder (without interest) as soon
as reasonably practicable following allocation.
If an Eligible Shareholder subscribes for an amount which is not exactly divisible by the Issue
Price, in calculating the number of Shares to be issued, all fractional entitlements will be rounded
down to the nearest whole number of Shares. ANP will not refund any resulting small excess in
subscription monies (i.e. A$5 or less) which will be deemed to form part of the aggregate issue
price for the Shares.
Payments must be made in Australian dollars.
Minimum application for Shares under the Offer is A$2,500.
Applications and payments may not be withdrawn or revoked.
7.3
Board discretion
Despite any other provision of these Terms and Conditions, the Board may, at its absolute
discretion, accept, reject, correct or amend your application under the Offer, including, without
limitation, if:
8.
(a)
the Board decides to increase or decrease the total amount to be raised under the Offer
including based on overall applications received in accordance with section 8 below;
(b)
the Board decides to scale back applications in accordance with section 8 below;
(c)
the Company considers that the application (whether alone or in conjunction with other
applications) does not comply, or it is not reasonably satisfied that the application
(whether alone or in conjunction with other applications) complies, with the requirements
of the ASIC Instrument or any other requirements in the ASX Listing Rules or the Act;
(d)
an application (including BPAY® payment) is received after 5.00pm (Sydney time) on the
Closing Date;
(e)
an application is made by a Custodian and does not include the required Custodian
Certificate;
(f)
the BPAY® payment received in respect of your application is for less than the full,
requisite amount; or
(g)
the Board is not reasonably satisfied that you are an Eligible Shareholder.
Discretion to vary amount raised and to scale back
The amount that each Eligible Shareholder can apply for under the Plan is capped at A$30,000.
ANP is targeting to raise up to approximately A$1.5 million under the Offer. The Company
reserves the right in its sole and absolute discretion to increase or decrease the final amount
raised under the Offer including based on overall applications received. Similarly, the Company
reserves the right to scale back applications in its sole and absolute discretion to the extent and in
the manner that the Board considers appropriate including as described further below. In all
cases, variations or scale backs will be in accordance with applicable laws and the ASIC
Instrument.
In accordance with Exception 5 of ASX Listing Rule 7.2, the aggregate maximum number of
Shares that will be issued under the Plan will not exceed 30% of the Shares on issue (and the
Issue Price of the Shares is 80% of the volume weighted average market price for the Shares
calculated in accordance with Exception 5 of ASX Listing Rule 7.2).
Should any scale back be necessary, it is the Company's intention that any scale back
arrangements will be made in the Company’s sole and absolute discretion. Any decisions made
by ANP will be final.
Antisense Therapeutics Limited | Share Purchase Plan
Page 10
If there is a scale back, Eligible Shareholders may receive less Shares than the number of Shares
for which they applied. If a scale back produces a fractional number of Shares when applied to a
particular parcel, the number of Shares allocated to an Eligible Shareholder will be rounded down
to the nearest whole number of Shares. The difference between the application monies received,
and the number of Shares allocated under the Offer multiplied by the Issue Price, will be refunded
to you, without interest, as soon as reasonably practicable following allocation.
9.
Issue of Shares
ANP intends to issue Shares under the Offer on the Issue Date (22 August 2023).
All Shares issued under the Plan will rank equally in all respects with all other Shares on issue as
at the date of issue and will carry the same voting rights, dividend rights and other entitlements as
those Shares.
ANP will apply for Shares issued under the Plan to be quoted on ASX. It is expected that they will
be quoted on ASX on, or shortly after, the Issue Date.
ANP will, within the period required by the ASX Listing Rules, send Eligible Shareholders, whose
application has been accepted by the Board, a holding statement in respect of any Shares issued
to them under the Plan.
10.
Acknowledgements
If you apply to participate in the Offer by submitting a BPAY® payment, you will be deemed to
have represented on behalf of each person on whose account you are acting that:
(a)
you warrant that you are, and each person on whose account you are acting is, an Eligible
Shareholder;
(b)
you agree that your application is made on, and you agree to be bound by, these Terms
and Conditions, any terms and conditions contained in your personalised application form
and ANP's constitution;
(c)
your application is irrevocable and unconditional;
(d)
the Company may in its sole and absolute discretion scale back any application and/or
participation in the Plan to the extent and in the manner it deems appropriate, including by
having regard to the pro rata shareholding of Eligible Shareholders who apply for Shares
under the Plan;
(e)
if there is a scale back you may receive less than the number of Shares for which you
have applied;
(f)
if your application results in a fractional number of Shares, the number of Shares you will
be allotted (subject to the other terms of the Offer, including in relation to any scale back)
will be rounded down to the nearest whole number of Shares;
(g)
the Shares have not been, and will not be, registered under the U.S. Securities Act or the
securities laws of any state or other jurisdictions in the United States, or in any other
jurisdiction outside Australia or New Zealand and accordingly, the Shares may not be
offered, sold or otherwise transferred except in accordance with an available exemption
from, or in a transaction not subject to, the registration requirements of the U.S. Securities
Act and any other applicable securities laws;
(h)
that the to
Share your feedback
Discover